### **Overview** Zota Health Care Limited (ZHCL) is a publicly listed Indian pharmaceutical company headquartered in Surat, Gujarat. Established in 2000, the company has evolved from a domestic pharmaceutical marketer into a vertically integrated healthcare player with a strong presence in **domestic marketing, international exports**, and **retail pharmacy through its flagship brand, Davaindia**. It operates under a mission to democratize access to affordable, high-quality healthcare in India and beyond. The company is strategically differentiated by its **360-degree integration** across the pharmaceutical value chain — combining **manufacturing, marketing, distribution, and retail** — enabling cost efficiency, supply chain control, and enhanced margins. --- ### **Core Business Segments** #### **1. Davaindia – Retail Pharmacy Chain (Primary Growth Driver)** - **Segment Contribution**: By H1FY26, Davaindia had become the **major revenue contributor**, with revenues growing rapidly due to aggressive expansion. - **Market Position**: India’s **largest private-sector generic pharmacy chain**, and the **third-largest private pharmacy retailer** by number of stores as of FY25. - **Store Network (as of Nov 2025)**: - **1,207** Company-Owned, Company-Operated (COCO) stores - **848** Franchisee-Owned, Franchisee-Operated (FOFO) stores - **Total: 2,055 stores** (across 25 states and union territories, spanning over 300 cities) - **Operating Model**: - **COCO**: Large-format, modern walk-in stores managed by wholly owned subsidiary **Davaindia Health Mart Limited**; ensures brand control, higher footfall, and superior customer experience. - **FOFO**: Asset-light franchise model enabling rapid, capital-efficient national expansion. - **Growth Strategy**: - **Cluster-based saturation approach** targeting high-density urban areas. - A **new store opened every 10 hours**; plans to add **800–900 new COCO stores by FY26**. - Strategic tie-up with **Indian Oil Corporation Limited (IOCL)** to launch Davaindia stores at petrol pumps, enhancing visibility and reach. - **Digital Expansion**: - Launch of B2C e-commerce platform (**davaindia.com** and mobile app) offering **doorstep delivery** across 2,000+ SKUs. - Utilizes **COCO stores as hyper-local fulfillment centers** to enable 60-minute delivery in select cities. - **Customer Metrics**: - **80% repeat customer rate**, indicating strong brand loyalty. - **Customer footfall** reached 97.7 lakh in FY24 (up from 51.8 lakh in FY23). - **Gross Merchandise Value (GMV)**: ₹24,562 lakh in FY24, up 78% YoY. #### **2. Domestic Marketing Business** - **Core Function**: Sources finished dosage forms (FDFs) from **WHO-GMP-certified Indian manufacturers**, subjects them to internal quality checks, and markets them under **private-label brands (Zota, Davaindia)**. - **Distribution Network**: - Over **1,050 exclusive, territory-based distributors** across India. - Direct-to-distributor model eliminates intermediaries like stockists and wholesalers. - **Product Portfolio**: - Over **4,000 SKUs** across generics, OTC, ayurvedic, nutraceutical, and wellness categories. - Strong focus on **chronic disease therapies** (cardiac, diabetes, thyroid, neuropsychiatric), which account for **57–60% of total revenue**. - **Revenue**: Historically the primary revenue driver until 2023; remains a stable contributor. #### **3. Exports** - **Manufacturing**: All exports are produced at the **Sachin (SEZ), Surat** facility, established in 2010 and **WHO-GMP certified in 2012**. - **Market Reach**: Products exported to **over 30 countries** across **CIS, Latin America, Africa, and Asia**. - **Regulatory Approvals**: - **325 approved dossiers** globally (as of Nov 2025). - **261 dossiers pending approval** — signaling an expanding international footprint. - Active focus on securing **Marketing Authorizations (MAs)** in each target country. - **Product Range**: **250+ generic formulations** tailored for international markets. - **Business Model**: Direct-to-market exports with full ownership of registrations, ensuring margin control and faster market access. --- ### **Strategic Initiatives & Backward Integration** #### **Acquisition of Everyday Herbal Group** - In **May 2024**, Zota acquired a **56% stake** (increased to **65.98%** by Oct 2025) in **Everyday Herbal Beauty Care Private Limited** and **Everyday Herbal Beauty and Wellness Care Private Limited**. - **Strategic Objective**: **Backward integration** into the Over-the-Counter (OTC) and wellness space. - **Key Benefits**: - **OTC products account for ~30% of total SKUs** and **~27% of FY25 revenue**. - Access to **Khadi and Village Industries Commission (KVIC) license** and **'Khadi' brand mark**, enhancing product credibility and appeal. - MOU allows use of **Government-recognized 'REGP' license**, adding regulatory strength. #### **Supply Chain & Logistics** - **Central Warehousing Hub**: A **state-of-the-art automated facility in Surat** managed via third-party logistics. - **Tech-Driven Operations**: - Cloud-based software and AI tools for real-time inventory, order, and shipment tracking. - Plans to **replicate the Surat warehouse model across multiple zones in India**. - **Outsourced 3PL model** supports scalability and operational efficiency. --- ### **Product & Pricing Strategy** - **Retail Model**: **100% private-label** model ensures complete control over branding and margins. - **Pricing Advantage**: - Offers **30–90% discounts** vs. branded equivalents. - Example: **Rosuvastatin 10mg at ₹25/10 tablets** (branded: up to ₹208). - **Margin Structure**: - Gross margins of **25–30%** — significantly lower than industry trade margins (~90%), allowing cost-pass-through to consumers. - **Focus on Chronic Therapies**: High repeat purchase behavior supports **patient retention and recurring demand**. --- ### **Financial Highlights (FY25, as of Mar 2025)** - **Revenue**: ₹2,929.75 million (~₹293 Cr) - **Gross Margin**: **53.13%** (high vs. peers — reflects strong pricing efficiency and low distribution costs) - **EBITDA Margin**: **–1.96%** (negative, due to aggressive store expansion and investment phase) - **Inventory Turnover**: 1.72 - **Working Capital Turnover**: 4.82 - **Working Capital Efficiency**: COCO stores operate **on a cash basis (zero receivables)**, improving cash flow profile. --- ### **Leadership & Governance** - **Dr. Sujit Paul**: Group CEO and industry veteran, driving strategic vision. - **Moxesh Ketanbhai Zota (MD & Executive)**: - Led international expansion into **30+ countries**. - Oversaw **325+ global product registrations**, with **261 in pipeline**. - **Kamlesh Rajnikant Zota (Whole-time Director)**: - Key in securing **regulatory approvals** (NAFDAC, TFDA, PPD) and managing **export compliance and patents**. - **Himanshu Zota**: Strategist behind **finance, taxation, and long-term planning**; instrumental in Davaindia rollout. - **Suniel Shetty**: Appointed **Brand Ambassador** in Aug 2025 to boost consumer trust and visibility. --- ### **Key Competitive Advantages** 1. **Vertically Integrated Model**: Control from manufacturing to retail ensures quality, cost efficiency, and margin protection. 2. **Asset-Light + Company-Owned Hybrid Expansion**: Balances scalability with operational control. 3. **Strong OTC & Chronic Care Focus**: High patient retention and recurring revenue. 4. **Digital-First Retail Strategy**: B2C e-commerce supported by physical network (COCO as fulfillment hubs). 5. **Regulatory Strength**: High number of international approvals and owned MAs. 6. **Backward Integration into OTC**: Enhances product mix and credibility via Khadi brand. ---